Triamterene

氨苯蝶啶

Report date: 2023/02/27 09:47:07
NME

Base Information

Drug NameTriamterene
Drug Alias NameTriamtereno三氨喋啶三氨苯蝶啶Triamterenum氨喋啶 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit blockers
TargetsSodium channel alpha subunit
Therapy Area/IndicationsEdemaHypertensionNephrotic Syndrome +[4] 
Global Approved IndicationsEdemaHypertensionNephrotic Syndrome +[4] 
Approved Indications in ChinaEdema
Original Approved Country/TerritoryJapan
Original Approved Date1962/12/01
Country/TerritoryUnited StatesUnited KingdomMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesConcordia
China Registration ClassN/A

Develop Information

Active CompaniesAdvanz Pharma CorpSuzhou Medison Pharmaceutical Co LTDMercury Pharmaceuticals Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsEdemaHypertensionNephrotic Syndrome +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeC03DB02
Related LinksWikipediaDrugBankKEGG